Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

NEW EPISODE
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
The Power of Timing: Therapies That Change Outcomes
The Power of Timing: Therapies That Change Outcomes
MinuteCE®
The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
In-Person & Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
MinuteCE®
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD, FASCO; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD, FASCO
- Javier Cortes, MD, PhD
0.75 program credits
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
MinuteCE®
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
MinuteCE®
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD, FASCO
- Javier Cortes, MD, PhD
0.75 program credits

Medical News

Medical News
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal Metastases
07/21/2026
Read more
Medical News
Talquetamab And Teclistamab Show Early Signal In Myeloma
07/20/2026
Read more
Medical News
MRI Radiomics Score And ADC Improve HCC Recurrence Prediction
07/20/2026
Read more
Medical News
ARCHER Trial Explores Vaccine Strategy to Prevent ALK Inhibitor Resistance in Advanced NSCLC
07/17/2026
Read more

CME/CE

Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
CME/CE Virtual Event
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
September 15, 2026
05:00 PM - 05:45 PM CEST
0.75 credits
NEW EPISODE
Precision in Practice—Bringing Targeted Therapy to mHSPC
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
What’s Next for TROP2-Directed ADCs in TNBC?
What’s Next for TROP2-Directed ADCs in TNBC?
MinuteCE®
What’s Next for TROP2-Directed ADCs in TNBC?
Tiffany Traina, MD, FASCO
0.75 program credits
- Tiffany Traina, MD, FASCO
0.75 program credits
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
September 24, 2026
03:30 PM - 04:30 PM ET
1.00 credit

Clinical Practice

Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Project Oncology®
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Alexandria May, PharmD, BCPS; Prithviraj Bose, MD
- Alexandria May, PharmD, BCPS
- Prithviraj Bose, MD
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD, FASCO
0.75 program credits
- Tiffany Traina, MD, FASCO
0.75 program credits
Personalizing Long-Term mCSPC Treatment Decisions
Personalizing Long-Term mCSPC Treatment Decisions
Project Oncology®
Personalizing Long-Term mCSPC Treatment Decisions
Charles Turck, PharmD, BCPS, BCCCP; Bilal Siddiqui, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Bilal Siddiqui, MD
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
September 03, 2026
02:00 PM - 03:00 PM ET
1.00 credit

Programs

MinuteCE®
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Tiffany Traina, MD, FASCO; Javier Cortes, MD, PhD
0.75 credits 6 episodes
- Tiffany Traina, MD, FASCO
- Javier Cortes, MD, PhD
0.75 credits 6 episodes
Applying Clinical Trial Data in mCSPC Care
Applying Clinical Trial Data in mCSPC Care
Project Oncology®
Applying Clinical Trial Data in mCSPC Care
Steve Jackson, PharmD; Jahan Aghalar, MD
- Steve Jackson, PharmD
- Jahan Aghalar, MD
- Ulka Vaishampayan, MD
Evidence-Based Treatment Decisions in Metastatic Triple-Negative Breast Cancer
Evidence-Based Treatment Decisions in Metastatic Triple-Negative Breast Cancer
Project Oncology®
Evidence-Based Treatment Decisions in Metastatic Triple-Negative Breast Cancer
Alexandria May, PharmD, BCPS; Neil M. Iyengar, MD
- Alexandria May, PharmD, BCPS
- Neil M. Iyengar, MD
Interpreting and Applying cGVHD Clinical Trial Data
Interpreting and Applying cGVHD Clinical Trial Data
Project Oncology®
Interpreting and Applying cGVHD Clinical Trial Data
Charles Turck, PharmD, BCPS, BCCCP; Christopher Graham, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Christopher Graham, MD